Search

Your search keyword '"marginal lymphom"' showing total 2 results
Start Over Descriptor "marginal lymphom"
2 results on '"marginal lymphom"'

1. ESMO Consensus conferences

Author

Andrew Wotherspoon, Johanna Kluin-Nelemans, Catherine Thieblemont, Pier Luigi Zinzani, Andrea Gallamini, S. Le Gouill, Martin Dreyling, Elias Campo, E. Iannitto, Emanuele Zucca, J. Rodriguez, Norbert Schmitz, Olivier Hermine, S. A. Pileri, Marco Ladetto, Luca Arcaini, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL), Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, and Zucca E

Subjects
Oncology, Pathology, medicine.medical_specialty, marginal lymphom, Lymphoma, Follicular lymphoma, mantle cell lymphoma, MINIMAL RESIDUAL DISEASE, Guidelines as Topic, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, T-Cell, World Health Organization, LOW-GRADE LYMPHOMA, INTERNATIONAL PROGNOSTIC INDEX, International Prognostic Index, immune system diseases, Internal medicine, hemic and lymphatic diseases, Humans, Medicine, T-cell lymphoma, NON-HODGKINS-LYMPHOMA, B cell, Hematology, business.industry, B-Cell, Malignant lymphoma guidelines, Mantle cell lymphoma, Marginal zone lymphoma, Europe, Lymphoma, B-Cell, Marginal Zone, Mantle-Cell, T-Cell, medicine.disease, marginal zone lymphoma, BONE-MARROW-TRANSPLANTATION, Peripheral T-cell lymphoma, medicine.anatomical_structure, EUROPEAN-MCL-NETWORK, malignant lymphoma guidelines, PROSPECTIVE RANDOMIZED-TRIAL, business, PHASE-II TRIAL, HIGH-DOSE THERAPY, PROGRESSION-FREE SURVIVAL
Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organizes consensus conferences to focus on specific issues in each type of tumour. In this setting, a consensus conference on the management of lymphoma was held on 18 June 2011 in Lugano, next to the 11th International Conference on Malignant Lymphoma. The conference convened similar to 30 experts from all around Europe, and selected six lymphoma entities to be addressed; for each of them, three to five open questions were to be addressed by the experts. For each question, a recommendation should be given by the panel, referring to the strength of the recommendation based on the level of evidence. This consensus report focuses on the three less common lymphoproliferative malignancies: marginal zone lymphoma, mantle cell lymphoma, and peripheral T-cell lymphomas. A first report had focused on diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia.

Published
2013

2. Nodal reactive and neoplastic proliferation of monocytoid and marginal zone B cells: an immunoarchitectural and molecular study highlighting the relevance of IRTA1 and T-bet as positive markers

Author

Stefano Pileri, Teresa Marafioti, Jennifer C. Paterson, Roshanak Bob, Harald Stein, Brunangelo Falini, Bob R, Falini B, Marafioti T, Paterson JC, Pileri S, and Stein H

Subjects
Adult, Male, Pathology, medicine.medical_specialty, marginal lymphom, Histology, Receptors, Fc, Immunoglobulin light chain, Polymerase Chain Reaction, Immunophenotyping, Pathology and Forensic Medicine, Biomarkers, Tumor, medicine, Humans, In Situ Hybridization, Fluorescence, B cell, Aged, Cell Proliferation, Aged, 80 and over, B-Lymphocytes, biology, Lymphoma, B-Cell, Marginal Zone, General Medicine, Middle Aged, medicine.disease, Marginal zone, Immunohistochemistry, Lymphoma, medicine.anatomical_structure, Lymphatic system, biology.protein, Female, Lymph Nodes, Antibody, T-Box Domain Proteins
Abstract

Aims: Marginal zone B cells (MZCs) and monocytoid B cells (MBCs) appear to be related lymphoid cells that take part in reactive and neoplastic marginal zone proliferations. These lesions are not yet well characterized, and the aim of this study was to find better diagnostic criteria for them. Methods and results: We analysed 60 nodal lesions with MBC and/or MZC proliferation for their morphological, immunophenotypic, molecular genetic and IG gene rearrangement features. On the basis of the results of the rearrangement assay and immunoglobulin light chain restriction, the lesions were divided into reactive and neoplastic groups. Among the neoplastic lesions, polymorphic and monomorphic subgroups emerged. All reactive lesions had morphological features of the polymorphic subgroup. By immunohistochemistry, IRTA1 and/or T-bet expression was found in all reactive lesions and in 90% of neoplastic lesions. Conclusions: IRTA1 and T-bet are positive markers for the identification of MZC/MBC proliferations, and thus for the diagnosis of nodal marginal zone lymphoma (NMZL). Polymorphic and monomorphic subgroups of NMZL could be distinguished. Most morphological and immunophenotypic patterns in reactive and neoplastic nodal expansions of MZCs and MBCs overlapped. Therefore, PCR clonality assay of the immunoglobulin heavy and light chain gene loci is the most reliable method for their differentiation. © 2013 John Wiley & Sons Ltd.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results